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AbstrACt
Objective To explore awareness about cervical cancer 
among Moroccan women attending an HIV treatment 
centre in Laâyoune city, Morocco.
Design A cross-sectional study was conducted from April 
to June 2017 using a knowledge test regarding cervical 
cancer, its risk factors and its prevention.
setting HIV treatment centre at the Hospital of Moulay 
Hassan Ben Elmehdi in Laâyoune city, Morocco.
Participants One hundred and twenty-three HIV-positive 
women aged 19 years and older were recruited to this 
study.
results A total of 115 women were eligible to participate 
in the study. The average age was 34.9±10.2 years. 
Few women (20%) had heard about cervical cancer 
and its screening, the majority (17.4%) having received 
information from mass media. The vast majority (79.1%) 
of respondents had no knowledge of cervical cancer risk 
factors, and 80.8% did not know any symptoms of cervical 
cancer. Only 13% had undergone a Pap smear test. The 
main reason for not seeking Pap smear was the absence 
of symptoms (47%).
Conclusion Our study documents poor awareness of 
cervical cancer. Given that the HIV-positive population 
is at increased risk of cervical cancer, health education 
programmes should be promoted to increase awareness 
of cervical cancer as well as access and participation in 
cervical cancer screening.
IntrODuCtIOn 
Cervical cancer is the fourth most common 
cancer in women worldwide, with an esti-
mated 527 624 newly diagnosed cases and 
265 672 deaths in 2012.1 Among newly diag-
nosed cases, 453 000 (86%) occurred mostly 
in low-income and middle-income coun-
tries.2 3 In Morocco, cervical cancer is a major 
public health problem. It is considered the 
second most common cancer in Moroccan 
women, after breast cancer, and the majority 
of women present to hospitals at late stages 
when treatment is less effective. Current esti-
mates indicate that 2258 new cases of cervical 
cancer and 1076 deaths from cervical cancer 
occur every year in Morocco.4 As in most 
low-income countries, there are no national 
screening or prevention programmes for 
cervical cancer in Morocco, and awareness of 
cervical cancer among women remains very 
limited.
Infection with human papillomavirus 
(HPV) is the most common sexually trans-
mitted infection (STI) worldwide. Among 
HPV genotypes, 40 have a tropism for the 
anogenital site, and persistent infection with 
one of a dozen high-risk HPV (hrHPV) is 
responsible for virtually all cases of cervical 
cancer and its precursors.5–7 Cervical cancer is 
one of the most preventable cancers. Indeed, 
effective primary and secondary prevention 
strategies for cervical cancer through HPV 
vaccination and cervical screening should 
reduce the infection and the incidence of 
precancerous cervical lesions that may subse-
quently progress to invasive carcinoma.
Women living with HIV present a 5.4-fold 
higher risk of developing cervical cancer 
than HIV-negative women.8 Indeed, 
strengths and limitations of this study
 ► To our knowledge, this is the first study to explore 
awareness of HIV-infected Moroccan women re-
garding cervical cancer.
 ► The study participants were recruited from a hospi-
tal and the findings might not be truly representative 
of HIV-infected women who do not have access to 
hospitals.
 ► This study was completed at one site and results 
cannot be generalised to all HIV treatment centres 
in Morocco.
 ► The small sample size limited further analysis for 
predictors of awareness about cervical cancer.
 ► The information provided by the participants could 
be affected by social acceptability bias and/or recall 
bias, despite our attempts to minimise this by en-
suring anonymity.
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HIV-infected women have a higher prevalence of hrHPV 
infection and greater persistence of HPV infection with 
multiple hrHPV types than HIV-negative women.9–13 
Several studies suggest that high HIV load and low CD4 
count are associated with an increased risk of hrHPV 
infection and cervical abnormalities among HIV-positive 
women.14–19
Cervical cancer has been classified as an AIDS-defining 
illness.20 With increased life expectancy following the 
introduction of antiretroviral therapy (ART), HIV-pos-
itive women are at high risk of precancerous lesions of 
the cervix and invasive cervical cancer due to immune 
suppression by HIV infection that appears to worsen 
the outcome of HPV infection.19 21–24 In a previous study 
performed among Moroccan women, we reported that 
26.2% of HIV-positive women screened for cervical cancer 
had abnormal results.25 Thus, the follow-up of women on 
ART offers an opportunity for cervical cancer screening 
in low-income and middle-income countries.26 27 In late 
2014, the number of people living with HIV in Morocco 
was estimated to be 28 892, with 51% of the cases regis-
tered between 2010 and 2014.28 As the primary preven-
tion of cervical cancer by HPV vaccination is not effective 
in women already infected by HPV, secondary prevention 
through early detection and treatment of precancerous 
lesions of the cervix is crucial.21 There is a national 
programme for cervical cancer screening for HIV-nega-
tive women in Morocco. It targets women aged between 
30 and 50 years. This programme aims to establish and 
to sustain the screening of women at risk in the primary 
healthcare structures. With regard to women living with 
HIV in Morocco, attendance at an HIV treatment centre 
is an opportunity to educate them about the risks of 
cervical cancer and the benefits of Pap smear screening. 
The purpose of this study was therefore to determine 
awareness on cervical cancer among women attending an 
HIV treatment centre in the city of Laâyoune, Morocco, 
in order to build a health education programme on 
cervical cancer and its prevention focusing on HIV-pos-
itive women.
MethODs
study design and setting
A cross-sectional study was conducted from April to June 
2017 to explore awareness of cervical cancer among 
HIV-positive women attending an HIV treatment centre at 
the Hospital of Moulay Hassan Ben Elmehdi in Laâyoune 
city. Laâyoune is situated in the South of Morocco, and 
it is considered the capital city of the Laâyoune-Bouj-
dour-Sakia El Hamra region. The total population of 
this area based on the 2014 census is estimated to be 
367 758.29 About 1400 cases representing 5% of the total 
number of notified HIV/AIDS cases in Morocco for the 
period 1986–2014 were diagnosed in women living in the 
Laâyoune region.28
study population
The inclusion criteria were HIV-positive women aged 19 
years old and above, volunteered to participate in the 
study and without mental or physical limitations that 
would preclude participation in focused discussions. 
Women reporting previous hysterectomy with removal 
of the uterine cervix and those unable to respond to the 
questions were excluded. Social class was based on the 
UK Registrar General’s Classification.30 31
Data collection
All HIV-positive women consulting the HIV treat-
ment centre for their follow-up (recommended every 
6 months) were informed and were offered participation 
in the study. The study period was limited to 3 months in 
order to reduce the possibility of interviewing the same 
patient twice. Women were subjected to a knowledge test 
guided by a questionnaire specifically designed for the 
present study.
The questionnaire was designed after reviewing publi-
cations reporting similar studies in the field of cervical 
cancer and its screening.32–34 Items were tested by a panel 
of physicians and were revised prior to its use in the study. 
The revised questionnaire was translated into the local 
dialect of the participants. It was read by a physician who 
transcribed and recorded the answers from the partici-
pants. Data collection took place in a private room for 
an average time of 15 min. The questionnaire consisted 
of three sections. The first section focused on sociode-
mographic and clinical characteristics of the subjects 
related to age, educational level, employment, marital 
status, place of residence, social class, sexual activity (age 
at first intercourse, lifetime sexual partners, contraceptive 
method), reproductive life (age at menarche, age at first 
pregnancy, parity), smoking, time since HIV-AIDS diag-
nosis, duration of ART, baseline CD4+ cell count, Centers 
for Disease Control and Prevention (CDC) stage and 
infection with other infectious diseases.
In the second section, awareness about cervical cancer 
was assessed if the answer to the question ‘Have you 
heard of cervical cancer?’ was ‘yes’. Respondents were 
then asked specific questions regarding knowledge of 
cervical cancer such as risk factors, symptoms, prevention 
and treatment. They were also asked about their source 
of information about cervical cancer; they were asked if 
they ever heard about cervical cancer screening, if they 
have already performed a Pap smear in their life and if 
they knew someone who suffered from cervical cancer. 
The third section was conducted to record reasons for 
not undergoing a Pap smear. Seropositivity and immune 
status were checked on the medical records of patients. 
After the interview, women were given counselling on 
cervical cancer screening.
statistical analysis
Data were entered into an Excel database and anal-
ysed using IBM SPSS Statistics V.20.0. In the descrip-
tive analyses, continuous variables are reported as 
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mean±SD. Categorical variables are described as number 
(percentage). Bivariate analysis using the χ2 statistics and 
Fisher’s exact test was performed to assess the relationship 
of the studied variables with awareness of cervical cancer. 
A p value <0.05 was considered statistically significant.
ethical considerations
The purpose and the importance of the study were 
explained to the participants. Confidentiality of the infor-
mation was maintained throughout the study by excluding 
personal identifiers from the data collection form.
Patient and public involvement
There was no patient or public involvement in this study.
results
Characteristics of the study population
A total of 123 HIV-positive women presented to the HIV 
treatment centre during the study period. Among them, 
eight (6.5%) were not eligible to participate in the study 
(four did not give their consent, three women reported 
previous hysterectomy and one woman had mental 
disease). Overall 115 women (93.5%) were included in 
the final analysis. The sociodemographic and clinical char-
acteristics of the study population are shown in table 1. 
The mean age (±SD) of the participants was 34.9 (10.2) 
years, with 14 (12.2%) women under 25 years old. The 
majority of women never attended school (71.3%) and 
were unemployed (80.9%). More than half of the women 
were divorced (54.8%), had menarche at age younger 
than 12 years (53.9%) and their first intercourse at age 
younger than 16 years (58.3%). Most participants resided 
in an urban area (95.7%) and 76.5% reported belonging 
to the lower social class. The majority of women (74.8%) 
reported having more than one lifetime sexual partner. 
More than half (54.8%) of women did not have any contra-
ception and 66.1% were nulliparous. According to their 
answers, 24.3% of women currently smoked. Time since 
HIV/AIDS diagnosis ranged from 1 month to 10 years, 
with a mean of 2.5±2.2 years. The mean duration on ART 
was 2.0±1.8 years. The majority of ART users (73.9%) had 
a CD4+ cell count between 200 and 500 cells/mm3, and 
53.1% of the participants were CDC stage A. Based on 
participants’ knowledge, seven women reported having 
had tuberculosis and two reported having had syphilis.
Awareness of women about cervical cancer
Responses to questions about awareness of cervical 
cancer among the population are summarised in table 2. 
Of the respondents, 24 (20.9%) and 22 (19.1%) had 
heard of cervical cancer and cervical cancer screening, 
respectively. Four women (3.5%) knew someone who 
had cervical cancer and only 15 (13.0%) reported that 
they had been screened for cervical cancer. Furthermore, 
when women were asked about the source of informa-
tion about cervical cancer, mass media (radio/television) 
was the predominant source (n=20, 17.4%), followed 
Table 1 Sociodemographic and clinical characteristics of 
Moroccan women followed in the HIV treatment centre in 
Laâyoune city, Morocco (n=115)
Characteristics n (%) Mean±SD
Age at interview (years) 34.9±10.2
  <30 34 (29.6)
  30–39 54 (47.0)
  40–49 17 (14.8)
  ≥50 10 (8.7)
Educational level
  Never attended school 82 (71.3)
  Primary school 24 (20.9)
  Secondary/high school 9 (7.9)
Employment
  No 93 (80.9)
  Yes 22 (19.1)
Marital status
  Single 2 (1.7)
  Married 40 (34.8)
  Divorced 63 (54.8)
  Widowed 10 (8.7)
Age at menarche (years) 12.64±1.42
  <12 62 (53.9)
  12–13 32 (27.8)
  >13 21 (18.3)
Age at first intercourse (years) 15.17±1.31
  <16 67 (58.3)
  ≥16 48 (41.7)
Place of residence
  Rural 5 (4.3)
  Urban 110 (95.7)
Social class
  Lower 88 (76.5)
  Middle 25 (21.7)
  Higher 2 (1.7)
Lifetime sexual partners
  Single 29 (25.2)
  Multiple 86 (74.8)
Actual contraceptive
method
  None 63 (54.8)
  Pill 39 (33.9)
  Condom 12 (10.4)
  IUD 1 (0.9) 
Parity 0.77 ± 1.42 
  0 76 (66.1)
  1 21 (18.3)
  >1 18 (15.6) 
Continued
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by friends/family (n=3, 2.6%) and health professionals 
(n=1, 0.9%).
To determine the overall awareness of cervical cancer, a 
series of questions on risk factors, main symptoms, preven-
tive measures and treatment options were asked to the 
study population. The vast majority of women (79.1%) 
had no knowledge of cervical cancer risk factors, while 
the 24 women who heard about cervical cancer (20.9%) 
were able to identify at least one risk factor associated 
with this disease. STIs and multiple sexual partners were 
mentioned as risk factors by 6.9% and 5.2% of these 24 
respondents, respectively, but no one identified HPV as a 
risk factor for cervical cancer. The vast majority (80.8%) 
of the respondents did not know any signs and symptoms 
of cervical cancer. Only 15 women (13%) mentioned 
offensive/excessive vaginal discharge, 6 (5.2%) abnormal 
bleeding between menstruations, and 1 (0.9%) bleeding 
and pain after sexual intercourse. Thirty-three (28.7%) 
women knew that cervical cancer can be prevented. 
The use of condoms (10.4%), having a regular Pap test 
(9.6%), limited number of sexual partners (7.8%) and 
delaying sexual debut (0.9%) were mentioned as helpful 
Characteristics n (%) Mean±SD
Smoking status
  Never smoked 46 (40)
  Former smoker 41 (35.7)
  Current smoker 28 (24.3)
Time since HIV/AIDS diagnosis 
(years)
2.5±2.2
  <1 48 (41.7)
  1–2 38 (33.1)
  >2 29 (25.2)
Duration of ART (years) 2.0±1.8
  <1 34 (29.6)
  1–2 43 (37.4)
  >2 38 (33)
Baseline CD4+ cell count among 
ART users (cells/mm3)*
  <200 8 (7.2)
  200–500 82 (73.9)
  >500 21 (18.9)
CDC stage*
  A 59 (53.1)
  B 29 (26.1)
  C 23 (20.8)
Had other infectious diseases
  None 106 (92.2)
  Tuberculosis 7 (6.1)
  Syphilis 2 (1.7)
*The baseline CD4+ cell count and the CDC stage for four 
patients were not found in their medical records.
ART, antiretroviral therapy; CDC, Centers for Disease 
Control and Prevention; IUD, intrauterine device.
Table 1 Continued Table 2 Awareness about risk factors, symptoms, 
prevention measures and treatment options of cervical 
cancer (CC) among HIV-positive women in Laâyoune city, 
Morocco
Items n %*
Ever heard of CC
  Yes 24 20.9
  No 91 79.1
Ever heard of CC screening
  Yes 22 19.1
  No 93 80.9
Knew someone with CC
  Yes 4 3.5
  No 111 96.5
Ever had a Pap smear
  Yes 15 13
  No 100 87
Knew risk factors for CC
  Sexually transmitted infection 8 6.9
  Multiple sexual partners 6 5.2
  Early onset of sexual activity 4 3.5
  Prolonged use of contraceptive pill 1 0.9
  Smoking 1 0.9
  No risk factor 2 1.7
  I didn’t know 91 79.1
Knew symptoms of CC
  Offensive vaginal discharge 10 8.7
  Excessive vaginal discharge 5 4.3
  Abnormal bleeding between 
menstruations
6 5.2
  Bleeding and pain after sexual 
intercourse
1 0.9
  I didn’t know 93 80.8
Knew prevention measures of CC*
  Use of condom 12 10.4
  Regular Pap test 11 9.6
  Limited number of sexual partners 9 7.8
  Delaying sexual debut 1 0.9
  I didn’t know 91 79.1
Knew treatment options of CC
  Chemotherapy 16 13.9
  Radiotherapy 1 0.9
  Surgery 5 4.3
  I didn’t know 93 80.8
*More than one options are reported by a participant.
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prevention measures. Only 19.1% of the respondents 
knew that cervical cancer can be treated using surgery, 
chemotherapy or radiotherapy.
reasons for not undergoing Pap smear screening
Only 15 participants have ever had at least one Pap smear. 
The 100 women (87%) who had never been screened for 
cervical cancer were asked for specific reasons for not 
undergoing Pap smear. The reasons for not accessing 
cervical cancer screening were absence of symptoms 
(47%), never heard of a Pap smear test (22%), fear of 
abnormal results (13%), fear of painful sampling (7%), 
shame or embarrassment (7%) and absence of sexual 
activity (3%).
sociodemographic and clinical characteristics associated 
with cervical cancer awareness
Bivariate analysis data of factors associated with cervical 
cancer awareness are presented in table 3. Significant 
associations have been observed with patients’ age, 
educational level, marital status, social class, contracep-
tive method, parity, time since HIV/AIDS diagnosis and 
duration of ART. Hence, patients above 40 years old were 
the most informed ones, with more than 59% aware of 
cervical cancer, whereas only 5.6% of women between 
30 and 39 years old were aware. With regard to educa-
tional level, the results show that women who never went 
to school were much less aware than school-educated 
women (63.6% vs 3.7%, p<0.001). Moreover, women in 
couples were the most aware ones in comparison with 
those living alone (50% vs 5.3%, p<0.001). Awareness of 
cervical cancer appeared to be also associated with social 
classes; women from higher social class were sixfold more 
aware of cervical cancer than women from lower social 
class. Women using contraceptive devices or pill were 
more aware in comparison with women who never used 
contraception. High parity, long time since HIV diag-
nosis or ARV treatment were also associated with cervical 
cancer awareness (p<0.01).
DIsCussIOn
Cervical cancer is a major public health issue worldwide 
and remains one of the most common malignancies among 
women in Morocco. The present data show that cervical 
cancer awareness was poor among women attending an 
HIV treatment centre in the city of Laâyoune, Morocco. 
About 80% of the HIV clinic population had never heard 
of cervical cancer and its screening. This finding is consis-
tent with other studies that reported lack of awareness 
about cervical cancer among HIV-positive women in other 
countries.35–37 However, it contrasts with similar studies 
carried out in South Africa and Kenya, where HIV-pos-
itive women were found to be well informed about this 
disease.38 39 This difference might be attributed to the fact 
that these two countries have a national cervical cancer 
screening policy. In our study, younger and women who 
never attended school were less aware about cervical 
cancer compared with school-educated women. This 
Table 3 Bivariate model for identification of factors 
associated with cervical cancer awareness among HIV-
positive women in the city of Laâyoune, Morocco
Characteristics
Aware of cervical cancer
No, n (%) Yes, n (%) P values
Age at interview (years)
  <30 29 (85.3) 5 (14.7) <0.001*
  30–39 51 (94.4) 3 (5.6)
  ≥40 11 (40.7) 16 (59.3)
Educational level
  Never attended  
school
79 (96.3) 3 (3.7) <0.001*
  School-educated 12 (36.4) 21 (63.6)
Employment
  No 74 (79.6) 19 (20.4) 0.50
  Yes 17 (77.3) 5 (22.7)
Marital status
  Married 20 (50.0) 20 (50.0) <0.001*
  Single, divorced,  
widowed
71 (94.7) 4 (5.3)
Age at menarche
  <12 19 (90.5) 2 (9.5) 0.37*
  12–13 47 (75.8) 15 (24.2)
  >13 25 (78.1) 7 (21.9)
Age at first intercourse
  <16 51 (76.1) 16 (23.9) 0.36
  ≥16 40 (83.3) 8 (16.7)
Residence
  Rural 4 (80.0) 1 (20.0) 0.7*
  Urban 87 (79.1) 23 (20.9)
Social class
  Lower 80 (91.0) 8 (9.0) <0.001
  Middle, higher 11 (40.7) 16 (59.3)
Lifetime sexual partners
  Single 22 (75.9) 7 (24.1) 0.39
  Multiple 69 (80.2) 17 (19.8)
Actual contraceptive  
method
  None 58 (92.1) 5 (7.9) 0.001
  Pill 25 (64.1) 5 (35.9)
  Condom, IUD 8 (61.5) 14 (38.5)
Parity
  0 67 (88.2) 9 (11.8) 0.001
  ≥1 24 (61.5) 15 (38.5)
Smoking status
  Never smoked 36 (78.3) 10 (21.7) 1
  Former smoker 33 (80.5) 8 (19.5)
  Current smoker 22 (78.6) 6 (21.4)
Continued
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agrees with data from studies conducted in other low-in-
come countries like Nigeria,37 Laos34 and Zimbabwe.40 
Education encourages female empowerment and may 
improve women’s knowledge of safe sex practices. Nullip-
arous women showed limited awareness about cervical 
cancer. This might be explained by the fact that they have 
never attended maternal and child health clinics.
In this study, mass media (radio/television) was the 
main source of information (17.4%) for most women, 
and only 4.2% of them reported health professionals 
as their source of information. This is in line with a 
study from Nigeria, where mass media was identified as 
the major source of information (23%) about cervical 
cancer.37 The role of media in the transfer of knowledge 
may become more effective when Moroccan govern-
ment will use it more actively in a policy of cancer 
prevention.
Having information on the causes and risk factors of 
cervical cancer is beneficial for a woman to take preven-
tive measures and to change behaviour. In this regard, 
none of the women knew that HPV infection is a cause 
of cervical cancer. Generally, there was low knowledge 
of the risk factors for cervical cancer, which is in agree-
ment with the findings of similar studies reported in 
Nigeria and Zimbabwe.36 37 40 Interestingly, the minority 
(20.9%) of women aware of cervical cancer were able to 
recognise at least one risk factor, such as STIs, multiple 
sexual partners, early onset of sexual activity, prolonged 
use of contraceptive pill and smoking. The abysmal 
level of knowledge among the youngest, unschooled 
and nulliparous population highlights the urgent need 
to improve education about cervical cancer prevention 
by vaccines and screening.41 We suggest that HIV care 
providers need to have health education sessions about 
cervical cancer risk factors when managing highly 
vulnerable women.
Another significant finding revealed that only few 
women in our study had undergone a Pap smear 
test. This is consistent with the fact that the majority 
of women (80.9%) were not aware of cervical cancer. 
This result confirms previous reports of low screening 
coverage among HIV-infected women, ranging from 
9% in Tanzania,42 10% in Nigeria,37 to 13% in South 
Africa.43 This low screening rate underscores the fact that 
women are not informed of the importance and bene-
fits of the Pap smear test in the prevention of cervical 
cancer. Indeed, in Morocco, cervical cancer screening 
is not part of HIV-positive prevention programme. 
However, close screening of cervical abnormalities in 
HIV-infected women, particularly in the era of inten-
sive widespread use of combination antiretroviral treat-
ment in sub-Saharan Africa and its consequences on the 
life expectancy of this highly at-risk population,44 is of 
crucial importance.
According to the results of our study, the main reason 
cited for not undergoing Pap smear was the absence of 
symptoms (47%). A similar reason was also reported 
by 46% of Lao women infected with HIV34 and 67% 
of female sex workers in a Thai study.45 This might be 
explained by lack of awareness among women on the 
natural history of cervical cancer and the principle 
of smear test screening. This stresses the necessity of 
including information about the natural course of 
cervical cancer in health prevention programmes.
A worrisome finding in this study is that more than 
90% of the respondents did not know that cervical 
cancer can be prevented, which is consistent with the 
findings of Eze et al,46 who reported that few women had 
knowledge of the prevention of cervical cancer. More-
over, only 19.2% of the respondents knew that cervical 
cancer can be treated, which is low compared with two 
studies from China where about 81% of the respon-
dents were knowledgeable of the potential curability of 
cervical cancer.47 48
The present work has some limitations that should be 
considered in interpreting the results. First, the study 
participants were recruited from a hospital; thus, the 
findings might not be truly representative of HIV-in-
fected women who do not have access to hospitals. 
Second, this study was completed at one site and results 
cannot be generalised to all HIV treatment centres in 
Morocco. Third, the small sample size limited further 
analysis for predictors of awareness about cervical 
cancer. Lastly, the information provided by the partici-
pants could be affected by social acceptability bias and/
Characteristics
Aware of cervical cancer
No, n (%) Yes, n (%) P values
Time since HIV/AIDS 
diagnosis (years)
  <1 27 (93.1) 2 (6.9) 0.009*
  1–2 33 (86.8) 5 (13.2)
  >2 31 (66) 16 (34)
Duration of ART (years)
  <1 31 (91.2) 3 (8.8) 0.003*
  1–2 37 (86.0) 6 (14.0)
  >2 23 (60.5) 15 (39.5)
Baseline CD4+ (cells/mm3)†
  <200 4 (66.7) 2 (33.3) 0.62*
  200–500 49 (76.6) 15 (23.4)
  >500 11 (68.8) 5 (31.2)
CDC stage†
  A 45 (76.3) 14 (23.7) 0.28*
  B 26 (89.7) 3 (10.3)
  C 17 (73.9) 6 (26.1)
*P value obtained with the Fisher’s exact test.
†The baseline CD4+ cell count and the CDC stage for four patients 
were not found in their medical records.
ART, antiretroviral therapy; CDC, Centers for Disease Control and 
Prevention; IUD, intrauterine device. 
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or recall bias, despite our attempts to minimise this by 
ensuring anonymity.
COnClusIOn
This is the first study demonstrating the extremely low 
level of awareness about cervical cancer and its risk 
factors, symptoms, prevention strategies and treat-
ment options among HIV-positive Moroccan women 
from south of Morocco. Thus, there is an over-riding 
need to implement and strengthen health education 
programmes on cervical cancer and its prevention in 
HIV treatment centres in Morocco. This study lays the 
groundwork to define changes in clinical practices 
regarding HIV-infected women who are at high risk of 
cervical cancer. It appears also necessary to evaluate 
healthcare providers’ knowledge and current prac-
tices to improve the prevention of cervical cancer in 
HIV treatment centres in Morocco.  Not discussing 
the potential role of HPV vaccines as a preventive tool 
against cervical cancer is also noted as an area of further 
investigation.
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